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The central challenges in tumor sequencing studies is to identify driver genes and pathways, investigate their functional relationships,
and nominate drug targets. The efficiency of these analyses, particularly for infrequently mutated genes, is compromised when subjects
carry different combinations of driver mutations. Mutual exclusivity analysis helps address these challenges. To identify mutually
exclusive gene sets (MEGS), we developed a powerful and flexible analytic framework based on a likelihood ratio test and a model
selection procedure. Extensive simulations demonstrated that our method outperformed existing methods for both statistical power
and the capability of identifying the exact MEGS, particularly for highly imbalanced MEGS. Our method can be used for de novo
discovery, for pathway-guided searches, or for expanding established small MEGS. We applied our method to the whole-exome
sequencing data for 13 cancer types from The Cancer Genome Atlas (TCGA).We identifiedmultiple previously unreported non-pairwise
MEGS inmultiple cancer types. For acutemyeloid leukemia, we identified aMEGSwith five genes (FLT3, IDH2,NRAS, KIT, and TP53) and
a MEGS (NPM1, TP53, and RUNX1) whose mutation status was strongly associated with survival (p ¼ 6.7 3 104). For breast cancer, we
identified a significantMEGS consisting of TP53 and four infrequentlymutated genes (ARID1A,AKT1,MED23, andTBL1XR1), providing
support for their role as cancer drivers.Introduction
Cancers, driven by somatic mutations, cause more
than eight million deaths worldwide each year. Recent
technical advances in next-generation sequencing and
bioinformatic analyses have greatly advanced the charac-
terization of tumor genomes. Large-scale cancer genomics
projects, e.g., the Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) for childhood
cancers, The Cancer Genome Atlas (TCGA), and the Inter-
national Cancer Genome Consortium (ICGC) for adult
cancers, have accumulated a large amount of multi-dimen-
sional genomic data for dozens of cancers. The primary
aim in analyzing these unprecedented ‘‘big’’ genomic
data is to identify ‘‘driver’’ mutation events related with
tumor initiation and progression. Typically, driver genes
are nominated by examining whether the non-synony-
mous mutation rate exceeds the background silent muta-
tion rate.1,2 However, identifying infrequently mutated
driver genes requires a very large sample size to achieve
statistical significance. A closely related challenge is to
investigate relationships among mutated genes and to
identify oncogenic pathways. Mutual exclusivity (ME)
analysis is an effective computational approach that helps
address both problems.
ME analysis was initially proposed for pairs of genes and
has produced important findings that have been consis-
tently replicated, e.g., ME between EGFR (MIM: 131550)
and KRAS (MIM: 190070) in lung adenocarcinoma.3–5
Because cancer pathways typically involve multiple genes,
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also has much better power than pairwise analyses. In
brief, given a somatic mutation matrix for N subjects and
M genes, we aim to identify ‘‘optimal’’ gene subsets that
are mutually exclusively mutated.
Multiple methods have been proposed for ME analysis.
Dendrix7 and two other methods9,10 use a ‘‘weight’’ statis-
tic as the criterion to search for MEGS. However, this
statistic is inappropriate to compare gene sets and tends
to identify large MEGS with many false-positive genes, as
we will show in simulations. MEMo6 uses external biolog-
ical data to form ‘‘cliques’’ (fully connected gene networks)
and searches for MEGS within each clique to increase po-
wer by reducing multiple testing. As we will demonstrate,
MEMo results in incorrect false-positive rates for each cli-
que and tends to select MEGS with false-positive genes.
Szczurek and Beerenwinkel8 proposed a non-standard like-
lihood ratio test but ended up with a severely misspecified
null distribution. Mutex11 has improved existing methods
and used permutations to control false-positive rates, but
its overly simple statistic warrants further improvement.
In summary, most of the existing methods fail to correctly
control for false-positive rates and lack a criterion for
selecting ‘‘optimal’’ MEGS. Because some of these MEGS
methods have been widely used in tumor sequencing
projects, previous results might need to be interpreted
with caution.
Ideally, an analytic framework for identifying MEGS
would have the following components. First, given a sub-
set of m (m % M) genes, a statistically powerful test is
required to examine whether mutations in these m genes, Bethesda, MD 20892, USA; 2Center for Cancer Research, National Cancer
y of Human Genetics. All rights reserved.
, 2016
show ME. Second, it is crucial to determine whether any
subset of the M genes is statistically significant after
adjusting for multiple testing. Third, a model selection
criterion is required to compare nested gene sets to select
the ‘‘optimal’’ MEGS. An inappropriate criterion can
falsely include genes into MEGS or exclude true genes
from MEGS.
We developed a framework that fits all above require-
ments. We developed a likelihood ratio test (LRT) for
testing ME and performed a multiple-path linear search
together with permutations to test the global null hypoth-
esis, i.e., the set of M genes does not contain MEGS of
any size. When global null hypothesis was rejected, we
proposed a model selection procedure based on permuta-
tions to identify ‘‘optimal’’ MEGS. All algorithms have
been implemented in an R package called MEGSA
(mutually exclusive gene set analysis). Extensive simula-
tions demonstrated that MEGSA outperformed existing
methods for de novo discovery and dramatically improved
the accuracy of recovering exact MEGS, particularly for
imbalanced MEGS. MEGSA can be used either for de
novo discovery or by incorporating existing biological da-
tasets (e.g., KEGG pathways and protein-protein interac-
tions) to improve statistical power by reducing multiple
testing, in spirit similar to MEMo6 and Mutex.11 We can
also use MEGSA to expand well-established small MEGS
with further improved power.
We applied MEGSA to analyze the whole-exome
sequencing data of 13 cancer types from TCGA. We identi-
fied multiple significant non-pairwise MEGS for breast
cancer, low-grade glioma, uterine corpus endometrial
carcinoma, skin cutaneous melanoma, head and neck
squamous cell carcinoma, and acute myeloid leukemia
with important biological implications. Incorporating
KEGG pathway data further identified eight MEGS for
breast cancer and ten for low-grade glioma. Although de
novo discovery has lower power due to the high multiple
testing burden, it has the potential to identify a more com-
plete MEGS. Incorporating external information might
identify significant but probably incomplete oncogenic
pathways. Thus, MEGSA should be applied using these
complimentary search strategies. We expect MEGSA to be
useful for identifying oncogenic pathways and driver
genes that would have been missed by frequency-based
methods.Material and Methods
We consider a binary mutation matrix A with N rows (subjects
with cancer) and M columns (genes), where each row represents
the mutational status for one subject and each column for one
gene (Figure 1A). Let aik denote the mutation status with aik ¼ 1
if gene k is somatically mutated for subject i and aik ¼ 0 otherwise.
Here, a somatic mutation could be copy-number alternations,
non-synonymous point mutations, or point mutations predicted
to be deleterious. We consider non-synonymous point mutations
in this manuscript. MEGSA has three components: (1) an efficientThe Amelikelihood ratio test (LRT) for examining mutual exclusivity for a
subset of genes, (2) a multiple-path linear search algorithm and a
permutation framework to evaluate the global null hypothesis
(GNH), and (3) a model selection procedure to identify the
‘‘optimal’’ MEGS.
A Likelihood Ratio Statistic for Testing Mutual
Exclusivity
Given a subset of m (m% M) genes and the binary mutation ma-
trix (denoted as A0, a sub matrix of A), we describe a data genera-
tive model for MEGS. We assume that the m genes in the MEGS
are completely mutually exclusive with coverage denoted as g,
defined as the proportion of samples covered by the MEGS.
Within the MEGS, we assume (p1,..., pm) as the relative mutation
frequencies with p1 þ ... þ pm ¼ 1. We assume that the observed
mutation matrix A0 is generated in three steps (Figure 1B):
(1) Given N subjects and coverage g, we randomly sample n
subjects coved by the MEGS according to the distribution
Bionomial(N, g).
(2) For each sampled subject covered by the MEGS, we
randomly choose a ‘‘mutated’’ gene according to (p1,..., pm).
(3) Independent of the MEGS, we randomly simulate back-
ground mutations to each entry of matrix A0 with gene-
specific background mutation rates P ¼ (p1,..., pm). Here,
background mutations refer to the mutations that do not
belong to the MEGS.
Based on this data generative model and further assuming
pkfpk, the log likelihood is given as
log Lðg;P;A0Þ ¼
XN
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Here, g¼ 0 corresponds to the null hypothesis that them genes are
randomly mutated. P ¼ (p1,..., pm) are nuisance parameters. LRT
can be derived to test H0: g ¼ 0 versus H1: g > 0. Asymptotically,
LRT has a null distribution 0:5c20 þ 0:5c21, a mixture distribution
with 0.5 probability at point mass zero and 0.5 probability as c21.
See Appendix A for details.
Testing the Global Null Hypothesis
Given a mutation matrix A with all M genes, it is crucial to test
GNH that all genes are mutated independently. Suppose that we
are interested in MEGS with no more than K genes. We havePK
k¼2

M
k

combinations of genes to be tested, which equals to
2.0 3 1011 if M ¼ 100 and K ¼ 8. The multiple testing burden in-
creases with size exponentially when K<M/2. Importantly, the to-
tal multiple testing burden is dominated by the largest MEGS with
K genes. WhenM ¼ 100 and K ¼ 8, the number of tests for MEGS
with 8 genes account for 91.5% of total 2.03 1011 tests while such
proportion is only 8.0 3 105% for MEGS of 3 genes. Intuitively,
for the same nominal p value of 106, a MEGSwith 3 genes should
be much more significant than the one with 8 genes. Thus,
putative MEGS of different sizes must be differentially treated.
Moreover, the statistical tests can be highly correlated; thus the
Bonferroni correction is too conservative. We propose a permuta-
tion-based procedure to address these problems (Figure 1C). Noterican Journal of Human Genetics 98, 442–455, March 3, 2016 443
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Figure 1. Overview of the Algorithms Implemented in MEGSA for Searching Mutually Exclusive Gene Sets
(A) Observed somaticmutationmatrix. Each row is for one sample and each column for one gene. Red entries representMEGSmutations
and gray entries represent background mutations.
(B) A data generative model for MEGS. The left panel shows a MEGS with four genes showing complete mutual exclusivity. The right
panel shows MEGS mutations and background mutations. g is the coverage of the MEGS, defined as the proportion of samples covered
by the MEGS. (p1,..., pm) are the relative mutation frequencies normalized to have p1 þ...þ pm ¼ 1. (p1,..., pm) are the background mu-
tation frequencies.
(C) Overall statistic for testing global null hypothesis and its significance. pij is the p value of our LRT for a gene pair (i, j). pijk is the p value
for a gene triplet (i, j, k). For each k, let Pk as the minimum p value of all sets of k genes and evaluate its significance (denoted as Qk) using
permutations preserving mutational frequencies. The overall statistic is defined as q ¼min(Q2,/, QK) and its significance is assessed by
permutations.
(D) Model selection based on permutations. Two nested putative MEGS—(G1,G2) and (G1,G2,G3)—have nominal p value p1 and p2 based
on LRT. We permute mutations in (G3, /, GM) by keeping the mutual exclusivity of (G1, G2) unchanged. G^k represents permuted mu-
tations for gene k. For each permutation, we calculate the minimum p value for all M-2 triplets (G1,G2, G^k). Threshold p0 is chosen at
level 5%.that permutations were performed by preserving the mutation fre-
quency for each gene.7,11
In brief, we first perform multiple test correction separately for
MEGS of each size. For a given k (k % K), we search all gene sets
of size k to test for ME using our LRT and denote the minimum
p value as Pk. The significance of Pk, (denoted as Qk) is estimated
by permutations. Because we search for MEGS of different sizes,
the overall statistic for testing GNH is q¼min(Q2,/, QK), with sig-
nificance evaluated by permutations. Finding the minimum p
value Pk by exhaustive search is computationally challenging
even for a moderate k. Thus, we implemented a multiple-path
linear search algorithm to approximate Pk (Appendix A).
Identifying Optimal Mutually Exclusive Gene Sets by
Model Selection
When GNH is rejected, we can use the multiple-path linear search
algorithm to identify all significant putativeMEGS. These putative
MEGS can be nested. Consider two significant putative MEGS:
MEGS1 has two genes (G1, G2) with nominal p value p1 and
MEGS2 has three genes (G1, G2, G3) with nominal p value p2 based
on LRT. Intuitively, if p2<<p1, we chooseMEGS2 with three genes.444 The American Journal of Human Genetics 98, 442–455, March 3However, a simple criterion p2 < p1 is too liberal and tends to
include G3 into MEGS even if G3 is independent of (G1, G2). This
is because G3 is chosen from the M-2 genes (G3, /, GM) to form
the strongest MEGS with G1 and G2.
We addressed the problem in a statistical testing framework
(Figure 1D). The null hypothesis is that none of the M-2 genes
(G3,/,GM) is mutually exclusive of (G1,G2). We reject the null hy-
pothesis (and thus choose MEGS2) if p2 < p0 with p0 chosen to
control false-positive rate < 5% based on permutations. Note
that we keep the relationship between G1 and G2 unchanged
and permute mutations only in (G3,/, GM). If (G3,/, GM) are in-
dependent of (G1, G2), using p0 as threshold will correctly choose
MEGS1 with probability 95%.
Identifying Mutually Exclusive Gene Sets by Three
Search Strategies
We propose three complimentary strategies for searching MEGS
via MEGSA, as illustrated in Figure 2. The first strategy is de
novo discovery by directly applying MEGSA to all M genes
(Figure 2A). The advantage of de novo discovery is that it does
not rely on any prior information and has the potential to identify, 2016
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Figure 2. Three Strategies for Searching Mutually Exclusive Gene Sets via MEGSA
(A) De novo analyses for all M genes.
(B) Search MEGS by incorporating KEGG pathways. For each pathway, we derive the subset (called a module) ofM genes (with mutation
data) in the pathway. We eliminate duplicate modules or modules with fewer than three genes and analyze each module via MEGSA to
derive module-wise p values. We control FDR < 0.05 using these module-wise p values to choose significant modules and identify
optimal MEGS.
(C) Expanding established small MEGS (G1, G2) by the model selection procedure described in Figure 1D.a complete MEGS. However, de novo analyses might have low po-
wer because of heavy multiple testing burden.
MEGSA can also be applied by incorporating existing biological
data, in spirit similar to MEMo6 and Mutex.11 MEMo searches for
fully connected sub graphs (called ‘‘cliques’’) using existing
pathway and functional information (e.g., protein-protein inter-
action and gene coexpressoin) and analyzes each clique. Mutex re-
stricts search space so that genes in MEGS have a common down-
stream signaling target. Although MEGSA can be modified to
perform similar search, we exemplify this approach by using the
KEGG pathway database (Figure 2B). In brief, we compareM genes
with KEGG pathways and identify subsets (called modules) with
more than two genes. We analyze each module using MEGSA
and produce an overall p value. We choose significant modules
by controlling FDR at 5%.
The third strategy is to search MEGS starting with a well-estab-
lished small MEGS (e.g., EGFR and KRAS in lung cancer). We use
ourmodel selection procedure (Figure 1D) to ‘‘grow’’ theMEGS un-
til no gene can be included (Figure 2C).Results
Type I Error Rate and Power Behavior of LRT
Because the LRT is the foundation for our algorithm, we
first evaluated its type I error rate and the power behaviorThe Amefor a fixed set of m genes. Under H0, LRT ~ 0:5c
2
0 þ 0:5c21
asymptotically. Results based on 100,000 simulations veri-
fied that the p values calculated based on the asymptotic
distribution agreed well with the simulation-based p values
(Table S1) for different combinations of parameters,
including background mutation rate, sample size, and
the size of gene sets. The power of LRT increases with sam-
ple size and coverage and reduces with background muta-
tion rates (Figure S1).Comparison with Other Methods that Detect
Mutually Exclusive Gene Mutations via Simulations
We compared the performance of MEGSA with the perfor-
mances of existing methods including RME,12 MEMo,6
Dendrix,7 LRT-SB,8 and Mutex.11 MDPFinder9 uses the
same ‘‘weight’’ statistic as Dendrix but a more efficient
computational method for searching MEGS; thus the
comparative study does not include MDPFinder. A system-
atic comparison is very difficult for following reasons. Den-
drix, RME, and LRT-SB perform de novo analyses; MEMo
uses existing biological data to reduce the search space;
and MEGSA and Mutex can perform both analyses. In
addition, for RME, Dendrix, and LRT-SB, it is unclearrican Journal of Human Genetics 98, 442–455, March 3, 2016 445
howmultiple testing was corrected. Mutex11 compared the
performances using receiver operating characteristic (ROC)
analysis, but it is unclear how false positives and false neg-
atives were calculated. A more detailed summary and
critique of these methods can be found in the Supple-
mental Note.
We empirically evaluated the null distribution of LRT-
SB.8 Simulation results show that the empirical distribu-
tion of LRT-SB deviates dramatically from the claimed
null distribution N(0,1) (Figure S2; see also the theoretical
explanation in Supplemental Note). MEMo derives a
p value for each ‘‘clique’’ and selects significant cliques
by controlling FDR using these p values. Controlling FDR
requires p values for null statistics to follow a uniform dis-
tribution U[0,1].13 However, our simulation results (under
H0) show that the p values dramatically deviate from the
uniform distribution U[0,1] (Figure S3), suggesting that
MEMo has incorrect false-positive rates. In addition,
MEMo does not select ‘‘optimal’’ MEGS sets appropriately
and typically includes many false positives (Figure S4 and
Supplemental Note). Therefore, we excluded LRT-SB and
MEMo from the comparison.
In the first set of simulations, we simulated a mutation
matrix for 54 genes in 500 samples. Among the 54 genes,
mutations in 50 genes were randomly distributed. The
50 genes were classified into five groups; each group had
10 genes with mutation frequencies 1%, 5%, 10%, 20%,
or 30%. The simulated MEGS had four genes. The back-
ground mutation rates for these four genes were set as
1%. We simulated two types of MEGS (Figure 3A). One
had balanced mutation frequencies, i.e., all four genes in
MEGS were mutated with the same frequency. The other
had imbalanced mutation frequencies with ratio 3:1:1:1.
Comparison was based on de novo analyses. The
maximum size of MEGSwas set as eight. The simulation re-
sults for MEGS with three genes are reported in Figure S5.
We first compared the performance of these methods as
a ‘‘scoring’’ method without considering the statistical sig-
nificance. Therefore, we calculated the probability of
choosing the true MEGS identified as the top candidate
for each method. Simulation results show that MEGSA
performs the best for all simulations and greatly improves
existing methods particularly for imbalanced MEGS
(Figure 3B). Of note, the performances are heavily
impacted by the coverage of the MEGS for all methods.
Dendrix has the worst performance and cannot identify
the true MEGS even when the coverage is high. RME per-
forms poorly for low-coverage MEGS but reasonably well
when coverage increases to 60% for balanced MEGS.
Mutex outperforms RME and Dendrix.
Among Dendrix, RME, Mutex, and MEGSA, only Mutex
and MEGSA performed permutations to accurately eval-
uate overall significance (either family-wise error rate or
FDR). Therefore, we compared the performance of these
two methods for statistically significant findings. For
MEGSA, a significant finding was identified if its multiple
testing corrected p value < 0.05. For Mutex, a significant446 The American Journal of Human Genetics 98, 442–455, March 3finding was identified if FDR < 0.05. A simulation was
considered successful if the detected top MEGS involved
any pair of the four genes in the simulated MEGS. The po-
wer is calculated as the proportion of ‘‘successful’’ simula-
tions (Figure 3C). A much more rigorous criterion required
that the top MEGS was statistically significant and iden-
tical to the simulatedMEGS (Figure 3D).We also calculated
the average number of correctly identified genes (out of
four) and number of falsely identified genes (Figure S6).
MEGSA outperforms Mutex in all comparisons. Impor-
tantly, the performance of MEGSA is superior to that of
Mutex for imbalanced MEGS, which are much more
frequent than balanced MEGS in real data.
Although the three methods (RME, Mutex, and MEGSA)
have different performances, the probability of choosing
the exactMEGS increases to onewhen sample sizes increase
to infinity, an important statistical property called ‘‘consis-
tency.’’ However, the widely used Dendrix algorithm does
not have this property and tends to includemany false-pos-
itive genes (see Supplemental Note for explanation). Here,
we report more detailed simulation results for Dendrix,
investigating the false positives in the selected top candi-
date. Figure 3E reports the probability of choosing each
gene based on 1,000 simulations assuming coverage
g ¼ 40% (top) and g ¼ 60% (bottom). Figure 3F reports
the distribution of the number of selected false-positive
genes. For example, when coverage g ¼ 40%, in about
30% of simulations, Dendrix’s top candidate includes
four false-positive genes. For low-coverage MEGS with
g¼ 40%, Dendrix chooses too many false positives, mostly
in highly mutated genes (frequency p ¼ 30%) and lowly
mutated genes (frequency p ¼ 1%). When coverage in-
creases to 60%, Dendrix identified almost all genes in
MEGS but still included many false-positive genes. These
simulation results suggest that a high-coverage MEGS
identified by Dendrix might include multiple false-
positive genes. Thus, MEGS identified by Dendrix might
need to be interpreted with caution. Encouragingly,
MEGSA has consistently high sensitivity and low false-
positive rates.
In the second set of simulations, we performed
simulations using the breast cancer tumor sequencing
data with 989 samples from The Cancer Genome Atlas
(TCGA). Our simulations were based on 39 driver genes
reported in the TumorPortal website. As we will show
in next section, TP53, CDH1, GATA3, and MAP3K1 were
detected as a highly significant MEGS for breast cancer
with estimated coverage bg ¼ 0:547, ðbp1; bp2; bp3; bp4Þ ¼
ð0:071;0:024;0:023; 0:015Þ and ðbp1; bp2; bp3; bp4Þ ¼ ð0:534;
0:180;0:173;0:113Þ. In each simulation, we simulated
MEGS mutation data with four genes (TP53, CDH1,
GATA3, MAP3K1) according to the estimated parameters
and randomly permuted the mutations across subjects
for the remaining 35 genes to generate background muta-
tions for these genes. We performed 1,000 simulations to
evaluate the performance. RME could not converge to pro-
duce results possibly because of multiple genes with low, 2016
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Figure 3. Performance Comparison of Methods for Detecting Mutually Exclusive Gene Sets on Simulated Datasets
In all simulations, we have 54 genes with 50 being randomly simulated with specific mutation frequencies and 4 genes as MEGS.
(A) Balanced and imbalanced MEGS with four genes. In imbalanced MEGS, the mutational frequencies have a ratio 3:1:1:1.
(B) Probability of ranking the exact MEGS as the top candidate. The X-coordinate is the coverage (g) of simulated MEGS.
(C) Power of detecting MEGS via MEGSA and Mutex.
(D) Probability that the identified topMEGS is statistically significant and identical to the true MEGS. Coverage (g) of MEGS ranges from
0.3 to 0.4.
(E) Probability of choosing each gene in the identified top MEGS by MEGSA and Dendrix. The top figure is based on a MEGS with
coverage g ¼ 0.4 and the bottom figure based on coverage g ¼ 0.6. p is the mutation frequencies for the 50 non-MEGS genes. The first
four are MEGS genes and the rest are non-MEGS genes.
(F) The distribution of the number of falsely detected genes for the topMEGS identified by inMEGSA andDendrix. MEGSAhad few false-
positive genes whereas Dendrix detected many false-positive genes.mutation frequencies. Thus, we compared the perfor-
mance for Dendrix, Mutex, and MEGSA. Dendrix included
many false-positive genes (mean of 2.8 false-positive genes
per simulations) and chose the trueMEGS as the top candi-
date in only 2% of simulations. Both Mutex and MEGSA
had low false-positive rates, including mean of 0.06
and 0 false-positive genes in each simulation, respectively.
MEGSA correctly chose the trueMEGS as the top candidate
in 93.4% simulations, and Mutex chose the true MEGS as
the top candidate in 33.2% simulations. Further investiga-
tion showed that Mutex missed one gene in 44.1% simula-
tions and two genes in 22.7% simulations. This set of
simulations based on realistic settings confirmed previousThe Amesimulation results that MEGSA had a better performance
for detecting the exact MEGS.
In the third set of simulations, we investigated the power
performance of MEGSA when input genes can be parti-
tioned into L modules of equal sizes by incorporating
pathway information. MEGSA was applied separately to
each module to generate a module-wise p value. A module
was statistically significant if its p value < 0.05/L based
on the Bonferroni correction. Under the assumption that
the true MEGS is completely contained in one of the
modules, the power of detecting MEGS can be substan-
tially improved compared to de novo analysis that simulta-
neously analyzes all genes (Figure S7).rican Journal of Human Genetics 98, 442–455, March 3, 2016 447
Analysis of TCGA Mutation Data
We analyzed non-synonymous point somatic mutations
identified by whole-exome sequencing for 13 cancers in
TCGAwith data downloaded from the data portal. For can-
cer types included in the TumorPortal website, we included
candidate driver genes reported by the website14 using
MutSigCV.1 Brain low-grade glioma (LGG) is not reported
in the TumorPortal website. Therefore we identified candi-
date driver genes using MutSigCV1 and included these
genes into analysis. Sample sizes, numbers of selected
genes, and mutational frequencies are summarized in
Tables S2 and S3. For each cancer type, we performed de
novo analysis followed by the secondary analysis incorpo-
rating KEGG pathways. For de novo analysis, gene
sets were considered statistically significant if p< 0.05 after
multiple testing based on 10,000 permutations. For KEGG-
guided analysis, we derived a module-wise p value for each
module and declared significance by controlling FDR <
0.05. Note that MEGS from pathway-guided analyses
were discarded if they were a subset of anyMEGS identified
in de novo analyses.
De novo analyses identified non-pairwise MEGS for
acute myeloid leukemia (LAML), LGG, breast invasive car-
cinoma (BRCA), skin cutaneous melanoma (SKCM), head
and neck squamous cell carcinoma (HNSC), and uterine
corpus endometrial carcinoma (UCEC). For other cancer
types, de novo analysis identified only pairwise MEGS.
Here, we report detailed results for BRCA and LAML. The
complete results are summarized in Table S4.
We also performed de novo analysis using RME,
Dendrix, and Mutex with results summarized in Table S5
and Figure S8. Because we lack the gold standard for accu-
rate comparison, we here briefly describe the putative
similarities and differences in the results produced from
these algorithms. When there existed strong MEGS with
high coverage, e.g., AKT1 (MIM: 164730), PTEN (MIM:
601728), and TP53 (MIM: 191170) with coverage 91.9%
in UCEC and BRAF (MIM: 164757), KIT (MIM: 164920),
and NRAS (MIM: 164790) with coverage 83.7% in SKCM,
Dendrix detected these MEGS with results consistent
with Mutex and MEGSA. However, when there were no
strong MEGS with high coverage, Dendrix selected a large
gene set as the top candidate, e.g., it chose a set of eight
genes (the maximum number of genes we allowed in anal-
ysis) as the top candidate for BRCA, GBM, KIRC, and
LAML. According to simulations, some of the genes from
these large putative MEGS might be false positives. RME
detected 25 MEGS; however, only two MEGS (pairwise)
were identical to those identified by Mutex or MEGSA
and the majority of them did not overlap with those by
Mutex or MEGSA. The mutation data did not seem to sup-
port the large MEGS identified by RME. MEGSA andMutex
produced the most similar results among the four algo-
rithms and detected 42 and 34 significant MEGS in total,
respectively. Among the 34 significant MEGS detected by
Mutex, 14 were identical to those identified by MEGSA,
11 were subsets of those in MEGSA, and 7 overlapped448 The American Journal of Human Genetics 98, 442–455, March 3with those in MEGSA for at least two genes. Mutex
frequently identified multiple subsets of one MEGS
identified by MEGSA. For example, MEGSA detected
EGFR, IDH1 (MIM: 147700), IDH2 (MIM: 147650), and
NF1 (MIM: 162200) whereas Mutex detected two subsets:
EGFR, IDH1, and IDH2 and IDH1, IDH2, and NF1. These
results together with the simulation results suggest that
MEGSA might have a better performance for identifying
a more complete oncogenic pathway. Mutex tends to
select smaller MEGS, consistent with its algorithm that
considers the weakest mutual exclusivity when scoring a
putative MEGS.
Analysis Results for BRCA
De novo analyses identified 10 significant but overlapping
MEGS for BRCA with 989 subjects. These MEGS involved
11 genes with TP53 involved in all MEGS (Figure 4A).
We identified five MEGS with p < 104 (Figure 4B). These
MEGS were not reported by the TCGA breast cancer
article15 using MEMo6 that relies on functional data,
emphasizing the necessity of de novo search.
Themost significant MEGS has four genes—TP53, CDH1
(MIM: 192090), GATA3 (MIM: 131320), and MAP3K1
(MIM: 600982)—and covers 59.6% of subjects. E-cadherin,
encoded by CDH1, is important in epithelial-mesen-
chymal transition (EMT). Moreover, GATA3, p53, and
MAP3K1 are related to the expression of CDH1. Loss of
p53 represses E-cadherin expression in vitro as a result
of CDH1 promoter methylation;16 GATA3 expression is
correlated with E-cadherin levels in breast cancer cells;17
and E-cadherin expression can be repressed by Snail/Slug
after activation by the MAPK/ERK pathway.17
The largest MEGS (p ¼ 0.022) has five genes—TP53,
AKT1, ARID1A (MIM: 603024), MED23 (MIM: 605042),
and TBL1XR1 (MIM: 608628)—covering 40.4% of subjects
(Figures 4C and 4D). Of note, this MEGS is extremely
imbalanced: all genes except TP53 are infrequently
mutated with frequency 1%–2% and could not be identi-
fied by other methods, consistent with the results of simu-
lations. TBL1XR1 belongs to and regulates the core
transcription repressor complexes NCoR/SMRT,18 and
p53 gene targets might be regulated by the SMRT in vitro
in response to DNA damage.19 ARID1A encodes BAF250a,
a component of the SWI/SNF chromatin-remodeling com-
plex that directly interacts with p53.20–23 Therefore, loss of
ARID1A might have a similar effect as p53 deficiency. The
mutual exclusivity between MED23 and other genes have
not been reported previously. MED23 is a subunit of the
mediator complex, a key regulator of gene expression,
and is required for Sp1 and ELK1-dependent tran-
scriptional activation in response to activated Ras
signaling.24–27 MED1 and MED17 directly interact with
p53,27 suggesting a possible connection between p53 and
MED23 via the mediator complex. Also, MED23 interacts
directly with the transcription factor ESX/ELF3,27 which
is downstream of AKT1 in the PI3K pathway. ESX-depen-
dent transcription after activation by AKT is key for cell, 2016
Figure 4. Analysis Results for TCGA Breast Cancer Whole-Exome Sequencing Data
p values were adjusted for multiple testing for all reported MEGS.
(A) A network constructed based on the ten significant MEGS. Thickness of the edges and sizes of the gene labels are proportional to the
times in the detected MEGS.
(B) Five significant MEGS with p < 104.
(C) A significant MEGS with five genes.
(D) Illustration showingMEGS pattern including protein products (colored blue) of AKT1, TP53, ARID1A,MED23, and TBL1XR1 in their
relevant biological pathways. Connections including activation and interaction as well as effects on gene expression and biological pro-
cesses are indicated. Components in the NCoR/SMRT and SWI/SNF complexes and the potential interaction of MED23 with p53 via the
overall mediator complex are not illustrated. Connections including activation (lines with arrow) and inhibition (bar-headed lines) as
well as end biological effects between the gene products are illustrated. Abbreviations are as follows: RTK, receptor tyrosine kinases; GFR,
growth factor receptor.proliferation and survival. In summary, these genes
have key roles in chromatin remodeling (TBL1XR1 and
ARID1A), gene expression regulation (MED23 and TP53),
and signaling (AKT1), and probably regulate a common
set of gene targets downstream of the p53, PI3K, and
MAPK/ERK signaling pathways that are important for cell
cycle control, survival, and proliferation.
Importantly, these infrequently mutated genes are
unlikely to achieve high statistical significance via fre-
quency-based driver gene test, e.g., MutSigCV.1 In fact, in
the TCGA breast cancer article,15 MED23 and ARID1A
were not reported as significantly mutated whereas
FOXA1 (MIM: 602294) and CTCF (MIM: 604167) were
reported only as ‘‘near significance.’’ Because MutSigCV is
highly sensitive to the choice of ‘‘Bagle’’ gene set for esti-
mating the silent mutation rate, a very large sample size
is required to replicate these findings. Given that TP53 isThe Amea well-established driver gene, the observed mutual exclu-
sivity provides strong and independent evidence for estab-
lishing these genes’ role as drivers.
Pathway-guided analysis identified eight MEGS that
were not detected by de novo analyses. Interestingly, we
found that CBFB (MIM: 121360) was mutually exclusive
of ARID1A, MED23, and TP53. As described above, p53
can interact with ARID1A in the SWI/SNF chromatin
remodeling complex via BRG1 (see Figure 4D for SWI/
SNF complex). The transcriptional coactivator CBFB is
known to interact with the tumor-suppressor RUNX1,
the predominant RUNX family member in breast
epithelial cells.28 RUNX1 interacts with SWI/SNF via
BRG129 and can act as transcriptional coactivator for p53
in response to DNA damage.30 Thus, we propose that the
loss of either one of these genes would be sufficient to
lead to abnormal SWI/SNF complexes and dysregulationrican Journal of Human Genetics 98, 442–455, March 3, 2016 449
Figure 5. Analysis Results for TCGA Acute Myeloid Leukemia Whole-Exome Sequencing Data
p values were adjusted for multiple testing for all reported MEGS.
(A) A network constructed based on the five significant MEGS. Thickness of the edges and sizes of the gene labels are proportional to the
times in the detected MEGS.
(B) The most significant MEGS with three genes: NPM1, RUNX1, and TP53.
(C) The mutation status of the triplet (NPM1, RUNX1, and TP53) is strongly associated with survival.
(D) A significant MEGS with five genes.
(E) Illustration showing MEGS pattern including protein products (colored blue) of FLT3, IDH2, KIT, NRAS, and TP53 in their relevant
biological pathways. Connections including activation (lines with arrow) and inhibition (bar-headed lines) as well as end biological
effects between the gene products are indicated. IDH2, which locates to the mitochondria, is shown outside (or in-part) of the illustrated
organelle for clarity and only the relevant components of glutamine (GLN) and glutathione (GSH) metabolism and TCA cycle are
indicated. PI3K pathway (receptor tyrosine kinases [RTK], FLIT3, and KIT), MAPK/ERK pathway (NRAS). Abbreviations are as follows:
ROS, reactive oxygen species, aKG, alpha-ketoglutarate; 2HG, 2-hydroxyglutarate; TCA, tricarboxylic acid cycle; GLN, glutamine;
GLU, glutamate; and GLS, glutaminase 2; GSH (glutathione).of chromatin-related epigenetics and gene expression,
leading to inhibition of apoptosis.
Breast cancer is highly heterogeneous with only two
genes—TP53 and PIK3CA (MIM: 171834)—with mutation
frequencies greater than 15% (Table S3). The majority of
genes have mutation frequencies around 1%–2%, making
it difficult to identify MEGS. We successfully identified
ten significant MEGS based on de novo analyses and
additional eight guided by KEGG pathways. Other biolog-
ical databases, e.g., functional data and Human Reference
Network in MEMo6 or the common downstream target
database in Mutex,11 could be used in the future to guide
the search of MEGS.
Analysis Results for LAML
Compared with other cancer types, AML genomes have
the lowest somatic mutation rates,1 with only 13 muta-
tions in coding regions in average. Such a low overall450 The American Journal of Human Genetics 98, 442–455, March 3(and also background) mutation rate suggests a good
statistical power even with a small sample size according
to our simulations (Figure S1). In fact, de novo analyses
identified five distinct but overlapping significant
MEGS. These significant MEGS involve nine genes with
TP53 and FLT3 (MIM: 136351) shared by four MEGS
(Figure 5A). The pathway-guided search did not detect
additional MEGS.
The most significant MEGS (Figure 5B) has three
genes—NPM1 (MIM: 164040), RUNX1 (MIM: 151385),
and TP53 (p < 104)—which is a subset of the top
MEGS (four genes and four fusions) reported by the
TCGA LAML article.31 We further tested the association
of the mutations in these three genes and their combi-
nations with survival, adjusting for age, stage, and
gender. Strikingly, the strongest association was detected
for the MEGS (p ¼ 6.7 3 104; Figure 5C) but not any
subset (PTP53 ¼ 0.002, PNPM1 ¼ 0.13, PRUNX1 ¼ 0.24,, 2016
PTP53/NPM1 ¼ 0.0034, PTP53/RUNX1 ¼ 0.0032, and
PRUNX1/NPM1 ¼ 0.042), suggesting the usefulness of the
MEGS for predicting clinical outcomes. Note that in the
LAML article, the top MEGS included CEBPA (MIM:
116897), which had 3 (out of 13) mutations co-occurring
with the triplet. In fact, including CEBPA into the triplet
lowered the LRT statistic from 25.1 to 22.7. Thus, our
model selection procedure excluded CEBPA. Moreover,
including CEBPA did not significantly improve the predic-
tion of survival (p ¼ 5.9 3 104 with CEBPA versus
p ¼ 6.7 3 104 without CEBPA). These results suggest
that the mutual exclusivity between CEBPA and other
genes is at least suspicious and requires independent
replication.
The largest MEGS (Figure 5D) has five genes—FLT3,
IDH2, KIT, NRAS, and TP53 (p ¼ 0.0099)—covering
55.1% of subjects. This MEGS was not reported by the
TCGA LAML article31 and was not detected by other
algorithms. Figure 5E describes important connections
between function/pathways for the five gene products,
suggesting biological plausibility. FLT3 and KIT encode re-
ceptor tyrosine kinases upstream of the PI3K and MAPK/
ERK signaling pathways, and NRAS is also part of MAPK/
ERK. Mutations activating these pathways or inactivating
TP53 are commonmechanisms that cancer cells use to pro-
liferate and escape apoptosis.32
Interestingly, we discovered that IDH2 belongs to this
MEGS. IDH2 encodes a mitochondrial enzyme that con-
verts isocitrate to a-ketoglutarate (aKG) in the tricarboxylic
acid cycle and in this process produces the antioxidant
nicotinamide adenine dinucleotide phosphate (NADPH),
which is necessary to combat oxidative damage/
stress.33,34 Mutant IDH2 is predicted to result in depletion
of a-KG, a decrease in NADPH, and production of 2-hy-
droxyglutarate (2-HG) and might elevate cytosolic reactive
oxygen species (ROS).35 Mutant IDH2 can result in epige-
netic effects on gene transcription (including DNA hyper-
methylation and histone demethylation), whereas loss of
p53 function can result in increased expression of DNA
methyltransferase 1 (DNMT1).16,36 Thus, a reasonable
explanation for the observed mutual exclusivity between
TP53 and IDH2 is that the loss of either protein activity
can result in similar aberrant gene methylation patterns
across the genome and dysregulated gene expression. We
also suggest a further novel hypothesis. Depleted a-KG
levels in IDH2 mutant cells might be replenished by the
conversion of glutamate to a-KG in the mitochondria.37
The provision of glutamate in the mitochrondria is regu-
lated by p53 via expression of the enzyme glutaminase
(GLS), which also regulates antioxidant defense function
in cells by increasing reduced glutathione (GSH) levels.38
Thus, IDH2 and TP53 mutations are mutually exclusive
because loss of both genes (or gene activity) would not
be conducive to tumorgenesis or survival as a result of
further depletion of aKG levels in the mitochondria and
DNA damage caused by high levels of ROS. The mutual ex-
clusivity between IDH2mutation and FLT3, KIT, and NRASThe Ameis also biologically plausible. Mutant IDH2 might also be
linked to the activation of RAS/ERK and the PI3K pathways
via ROSs, which can act as potent mitogens when
apoptosis is inhibited.39 Elevated ROS levels can activate
ERKs, JNKs, or p38 and reversibly inactivated PTEN.40,41
Thus, IDH2 mutation might be sufficient to exclusively
deregulate cell proliferation and survival processes impor-
tant for AML development.Discussion
We developed a powerful and flexible framework, MEGSA,
for identifying mutually exclusive gene sets (MEGS).
MEGSA outperforms existing methods for de novo ana-
lyses and greatly improves the capability of recovering
the exact MEGS, particularly for highly imbalanced
MEGS. The key components of MEGSA are a likelihood
ratio test and a model selection procedure. Because likeli-
hood ratio test is asymptotically most powerful, MEGSA
is expected to be nearly optimal for de novo search. Our
algorithms can be easily adapted to other methods that
integrate with external information, e.g., MEMo and Mu-
tex, to improve performance. As an important contribu-
tion, we carefully examined the performance of existing
methods. We concluded that many methods had incorrect
false-positive rates and poor performance for selecting
optimal MEGS. Importantly, mutual exclusivity analysis
might help identify infrequently mutated driver genes, as
we demonstrated in the TCGA BRCA data. CoMEt42 was
recently published for identifying MEGS using the approx-
imate p value of an exact test as the scoring criterion.
CoMEt has to specify the size of MGES and it is not clear
how CoMEt compares nested putative MEGS models to
select the optimal one.
MEGSA can be further improved in several ways. First,
MEGSA does not consider the extremely variable somatic
mutation rates across subjects. Including subjects with
very high mutation rate might increase the background
mutation rate and thus decrease the statistical power.
We are currently extending MEGSA by modeling subject-
specific background mutation rates. Second, MEGSA
uses a multiple-path search algorithm for computational
consideration and might miss findings. The Markov Chain
Monte Carlo (MCMC) or the genetic algorithm might
address the issue.
In the current manuscript, we analyzed TCGA non-syn-
onymous point mutations for the purpose of testing the
MEGSA algorithm. We plan to extend the analysis to
include somatic copy-number aberrations (SCNAs), recur-
rent gene fusions,31 and epigenetic alternations. Moreover,
it would be extremely interesting to restrict analysis to
clonal point mutations that are carried by all cancer cells.
Clonal mutations happen before the most recent common
ancestor and are located early in the evolution tree of the
tumor;43 thus, clonal mutations are probably relevant for
tumorigenesis. Focusing the analysis on clonal mutations,rican Journal of Human Genetics 98, 442–455, March 3, 2016 451
although technically challenging,44–46 can substantially
reduce the background mutation rates and consequently
improve statistical power. More importantly, this refined
analysis might better reveal oncogenic pathways related
with tumorigenesis.Appendix A
A Likelihood Ratio Statistic for Testing Mutual
Exclusivity
Suppose that a MEGS has m genes with mutation matrix
denoted as A0. We assume that them genes are completely
mutually exclusive. A MEGS is characterized by two
parameters: the coverage g, defined as the proportion
of samples covered by the MEGS, and the relative muta-
tion frequencies P ¼ (p1,..., pm). Background mutations
are mutually independent and also independent of
the MEGS mutations. We allow different background
mutation rates P ¼ (p1,..., pm) for different genes. See
Figure 1B.
For subject i, let (ai1,..., aim) be the observed binary
mutation vector for m genes. Let Ci be a discrete binary
variable. If the subject is not covered by the MEGS,
Ci ¼ 0. If the subject has a mutation in gene k in
the MEGS, then Ci ¼ k. The likelihood of observing
(ai1,..., aim) is given byPðai1;/; aimÞ ¼
Xm
k¼0
Pðai1;/; aim j Ci ¼ kÞPðCi ¼ kÞ
¼ Pðai1;/; aim j Ci ¼ 0ÞPðCi ¼ 0Þ þ PðCi > 0Þ
Xm
k¼1
Pðai1;/; aim j Ci ¼ kÞPðCi ¼ k j Ci > 0Þ
¼ PðCi ¼ 0Þ
Ym
j¼1
P

aij j Ci ¼ 0
þ PðCi > 0ÞXm
k¼1
PðCi ¼ k j Ci > 0Þ
Ym
j¼1
P

aij j Ci ¼ k

:
(Equation A1)The last equation holds because mutations are indepen-
dent across genes. By the definition of coverage,
PðCi > 0Þ ¼ g and PðCi ¼ 0Þ ¼ 1 g: (Equation A2)
Also,
PðCi ¼ k j Ci > 0Þ ¼ pk: (Equation A3)
If the subject is not covered by the MEGS,
Pðaik ¼ 1 j Ci ¼ 0Þ ¼ pk: (Equation A4)
Furthermore,
P

aij ¼ 1 j Ci ¼ k
 ¼ 1 if j ¼ k
pj if jsk
: (Equation A5)452 The American Journal of Human Genetics 98, 442–455, March 3Combining Equations A1, A2, A3, A4, and A5, we have
Pðai1;/; aimÞ ¼ ð1 gÞ
Ym
k¼1
p
aik
k ð1 pkÞ1aik
þ g
Xm
k¼1
pkIfaik¼1g
Y
jsk
p
aij
j

1 pj
1aij :
The total likelihood across N subjects is
log L

g;P; P;A0
 ¼XN
i¼1
log
 
ð1 gÞ
Ym
k¼1
p
aik
k ð1 pkÞ1aik
þ g
Xm
k¼1
pkIfaik¼1g
Y
jsk
p
aij
j

1 pj
1aij!:
(Equation A6)
We test H0: g ¼ 0 versus H1: g > 0. P ¼ (p1,..., pm) and
P ¼ (p1,..., pm) are nuisance parameters. Although both
parameters can be estimated under H1, P ¼ (p1,..., pm) is
not involved in the likelihood under H0, which causes
problems in deriving the asymptotic null distribution
for the likelihood ratio test (LRT). To overcome this prob-
lem, we further assume that the MEGS mutation fre-
quencies are proportional to the background mutation
frequencies, i.e., pkfpk. Under this assumption, Equation
A6 reduces tolog L

g;P;A0
¼XN
i¼1
log
 
ð1 gÞ
Ym
k¼1
p
aik
k ð1 pkÞ1aik
þ g 1Pm
j¼1pj
Xm
k¼1
pkIfaik¼1g
Y
jsk
p
aij
j

1 pj
1aij!:
(Equation A7)
Let bP1 and bg1 be the estimate under H1 and bP0 be
the estimate under H0. The LRT is calculated as
S ¼ 2ðlog Lðbg1; bP1;A0Þ  log Lð0; bP0;A0ÞÞ. Asymptotically,
LRT has a null distribution 0:5c20 þ 0:5c21, a mixture distri-
bution with 0.5 probability at point mass zero and 0.5
probability as c21.
We have two comments. First, the assumption pkfpk
does not affect the null distribution of LRT because pk is, 2016
not involved in the data generation process under H0.
However, violation of this assumption might cause power
loss, which warrants further investigation. Second, the LRT
in the LRT-SBmethod was derived based on a different data
generative model, which incorrectly and unnecessarily
assumed that background mutations could happen only
for subjects covered by the MEGS. Under this model, their
likelihood function degraded as the coverage g/0, pre-
venting them from using the standard statistical theory
to derive the null distribution. To overcome this problem,
they used Vuong’s47 method (but incorrectly) to derive an
incorrect asymptotic null distribution. More details are in
the Supplemental Note.Testing the Global Null Hypothesis
Our algorithm for testing the global null hypothesis (GNH)
has the following steps. (1) For k% K k, we search all gene
sets of size k from M genes to test for ME using LRT and
denote the minimum p value as Pk. (2) We run T permuta-
tions, calculate the minimum LRT p value Pk(t) for permu-
tation t, and estimate the significance (denoted as Qk)
of the observed Pk as the proportion of simulations
with Pk(t) smaller than the observed Pk. Intuitively, Qk
measures the significance when searching only for
MEGS of size k. (3) Because we search for MEGS of different
sizes, the overall statistic for testing GNH is defined as
q ¼ min(Q2,/, QK), with overall significance evaluated by
permutations again.
Although conceptually straightforward, it is computa-
tionally infeasible. Finding the minimum p value Pk even
for a moderate k (e.g., k ¼ 6) is computationally very chal-
lenging and not feasible for thousands of permutations.
We propose a multiple-path search algorithm to address
the problem. In brief, we calculate the p values for
all M(M-1)/2 pairs of genes and choose the top L (e.g.,
L ¼ 10) pairs to start linear search. For the lth pair
(assuming G1 and G2), let q2(l) be the LRT p value.
Next, we calculate the LRT p values for M-2
triplets (G1,G2,G3), /, (G1,G2,GM) and choose the gene
(assuming G3) with the smallest p value, denoted as q3(l).
We repeat until qK(l). For each k, we approximate Pk by
minl%LqkðlÞ, instead of exhaustive search.Identify Statistically Significant MEGS
Remember that we use q ¼ min(Q2,/,QK) as the overall
statistic for testing GNH. Once GNH is rejected at level
a ¼ 0.05, we need to identify all combinations of genes
that reach significance. First of all, based on permuta-
tions, we can identify a cut-off q1-a. In the multiple-path
search algorithm described above, for each combination
of k genes, we transform its nominal LRT p value toQ based
on permutations and declare this gene set as significant if
Q<q1-a. This procedure can identify significant but nested
putative MEGS. We designed a model selection procedure
described in Figure 1D to make a choice between nested
models.The AmeSupplemental Data
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